Cargando…

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer

Detalles Bibliográficos
Autores principales:	Sartore-Bianchi, Andrea, Valtorta, Emanuele, Amatu, Alessio, Veronese, Silvio, Lauricella, Calogero, Bonazzina, Erica, Siravegna, Giulia, Truini, Mauro, Bardelli, Alberto, Siena, Salvatore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070243/ https://www.ncbi.nlm.nih.gov/pubmed/27843629 http://dx.doi.org/10.1136/esmoopen-2016-000079

Ejemplares similares

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2023)

Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2021)

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2017)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
por: Amatu, Alessio, et al.
Publicado: (2022)

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
por: Amatu, Alessio, et al.
Publicado: (2015)

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
por: Amatu, Alessio, et al.
Publicado: (2016)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2015)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
por: Patelli, Giorgio, et al.
Publicado: (2021)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report
por: Metro, Giulio, et al.
Publicado: (2015)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
por: Patelli, Giorgio, et al.
Publicado: (2023)

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2009)

Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
por: Liu, Tingting, et al.
Publicado: (2023)

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
por: Amatu, A, et al.
Publicado: (2019)

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2023)

COAMPLIFICATION OF THE hst‐1 AND int‐2 GENES IN HUMAM CANCERS
por: Tsutsumi, Masakazu, et al.
Publicado: (1988)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2009)

Coamplification of the L‐myc and N‐myc Oncogenes in a Neuroblastoma Cell Line
por: Jinbo, Takeshi, et al.
Publicado: (1989)

Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients
por: Patelli, Giorgio, et al.
Publicado: (2022)

Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids
por: Mauri, Gianluca, et al.
Publicado: (2021)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

Early‐onset colorectal cancer in young individuals
por: Mauri, Gianluca, et al.
Publicado: (2018)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2011)

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
por: Crisafulli, Giovanni, et al.
Publicado: (2019)

CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression
por: Yanai, Yoshinori, et al.
Publicado: (2020)

Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance
por: Siravegna, Giulia, et al.
Publicado: (2014)

Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
por: Crisafulli, Giovanni, et al.
Publicado: (2022)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
por: Amodio, Vito, et al.
Publicado: (2021)

Strategies to tackle RAS-mutated metastatic colorectal cancer
por: Patelli, G., et al.
Publicado: (2021)

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
por: Korpanty, Grzegorz J., et al.
Publicado: (2014)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy
por: Floros, Konstantinos V., et al.
Publicado: (2018)

Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas
por: Simon, Einav, et al.
Publicado: (2017)

Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis.
por: Borg, A., et al.
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_hlcut0kq0m1g7nq61ju5j8j43g